UCB is a global biopharma company focused on severe diseases in two therapeutic areas: central nervous system and immunology. Operating in approximately 40 countries, UCB aspires to be a patient-centric biopharmaceutical leader transforming the lives of people living with severe diseases. The environmental strategy defined six strategic pillars with corresponding key performance indictors (KPIs) ensuring regulatory compliance.
UCB developed and implemented their environmental strategy and commissioned Ecomatters as a thir-party reviewer of the strategy. It is important to elicit third party reviews as this keeps assessment results unbiased and valid.
Ecomatters conducted a general review of UCB’s environmental strategy. We assessed UCB’s six strategic pillars and coverage of the reported key performance indicators. Furthermore, we conducted benchmarking analysis of similar companies using publicly reported information.
According to the results of the benchmarking comparison and the review of standard reporting framework requirements (the Global Reporting Initiative and the EU Eco-Management and Audit Scheme), we proposed new KPIs and made recommendations to increase UCB’s “Environmental performance”.